Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
暂无分享,去创建一个
P. Fasching | T. Tankova | N. Lalic | D. Rahelić | A. Janež | I. Konrāde | Fahim Ebrahimi | G. Schernthaner | N. Shehadeh | J. Škrha | P. Kempler | C. Serafinceanu | B. Mankovsky | A. Ametov | A. Bazarova | E. Martinka | Ž. Visockienė